The EuroQol Group after 25 years

The EuroQol Group After 25 Years

Volumn , Issue , 2013, Pages 1-288

  Brooks, Richard ^a  

^a EuroQol Group   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84932118210     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-94-007-5158-3     Document Type: Book

References (306)

1. Burström, K., Egmar, A.-C., Lugnér, A., Eriksson, M., Svartengren, M. (2011): A Swedish child-friendly pilot version of the EQ-5D instrument-the development process. European Journal of Public Health; 21(2):171-7
2. Gusi, N., Badía, X., Herdman, M., Olivares, P.R. (2009):Translation and cultural adaptation of the Spanish version of EQ-5D-Y questionnaire for children and adolescents. Atencionprimaria; 41(1): 19-23.
3. Ungar, W. J. (2011): Challenges in health state valuation in pediatric economic evaluation: are QALYs contraindicated? Pharmacoeconomics; 29(8): 641-52.
4. Wille, N., Badia, X., Bonsel, G., Burström, K., Cavrini, G., Devlin, N., Egmar, A.-C., Greiner, W., Gusi, N., Herdman, M., Jelsma, J., Kind, P., Scalone, L., Ravens-Sieberer, U. (2010): Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Quality of Life Research; 19(6):887-97.
5. Eidt-Koch, D., Mittendorf, T., Greiner, W. (2009): Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany. BMC Pediatrics; 9:55.
6. Ravens-Sieberer, U., Wille, N., Badia, X., Bonsel, G., Burstrom, K., Cavrini, G., Devlin, N., Egmar, A.-C., Gusi, N., Herdman, M., Jelsma, J., Kind, P., Olivares P.R., Scalone, L., Greiner, W. (2010): Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Quality of Life Research; 19(6): 887-97.
7. Boyle, S. E., Jones, G. L., Walters, S. J. (2010): Physical activity, quality of life, weight status and diet in adolescents. Quality of Life Research; 19(7): 943-54.
8. Burström, K., Svartengren, M., Egmar, A.-C. (2011): Testing a Swedish childfriendly pilot version of the EQ-5D instrument-initial results. European Journal of Public Health; 21(2): 178-83.
9. Jelsma, J. (2010): A comparison of the performance of the EQ-5D and the EQ-5D-Y health-related quality of life instruments in South African children. International Journal of Rehabilitation Research; 33(2):172-7.
10. Jelsma, J., Ramma, L. (2010): How do children at special schools and their parents perceive their HRQoL compared to children at open schools? Health and Quality of Life Outcomes; 8:72.
11. Nordyke, K., Norström, F., Lindholm, L., Carlsson, A., Danielsson, L., Emmelin, M., Högberg, L., Karlsson, E., Ivarsson, A. (2011): Health-related quality-of-life in children with coeliac disease, measured prior to receiving their diagnosis through screening. Journal of Medical Screening; 18(4):187-92.
12. Oluboyede, Y., Tubeuf, S., McCabe, C. (2011): Measuring health outcomes of adolescents: report from a pilot study. European Journal of Health Economics; online first, July 2011.
13. Willems, D. C., Joore, M. A., Nieman, F. H., Severens, J. L., Wouters, E. F., Hendriks, J. J. (2009): Using EQ-5D in children with asthma, rheumatic disorders, diabetes, and speech/language and/or hearing disorders. International Journal of Technology Assessment in Health Care; 25(3): 391-9.
14. Wu, X.Y., Ohinmaa, A., Veugelers, P.J. (2012): Diet quality, physical activity, body weight and health-related quality of life among grade 5 students in Canada. Public Health Nutrition; 15(1): 75-81.
15. Wu, X. Y., Ohinmaa, A., Veugelers, P. J. (2010): Sociodemographic and neighborhood determinants of health-related quality of life among grade-five students in Canada. Quality of Life Research; 19(7):969-76.
16. Burström K., Egmar A-C., Sun S., Eriksson M., Svartengren M. (2010): Utveckling av EQ-5D-Y-en barnvänlig version av det hälsorelaterade livskvalitetsinstrumentet EQ-5D. (Development of EQ-5D-a child-friendly version of the health-related quality of life instrument EQ-5D.) Stockholm: Karolinska Institutets Folkhälsoakademi, 2010. Rapport 2010:22. (Karolinska Institutet School of Public Health, 2010. Report 2010:22.) (In Swedish).
17. Noyes, J., Edwards, R.T. (2011): EQ-5D for the assessment of health-related quality of life and resource allocation in children. A systematic methodological review. Value in Health; 14(8):1117-29.
18. Scalone, L., Tomasetto, C., Matteucci, M.C., Selleri, P., Broccoli, S., Pacelli, B., Cavrini, G. (2011): Assessing quality of life in children and adolescents: Development and validation of the Italian version of the EQ-5D-Y. Italian Journal of Public Health; 8(4): 331-341.
19. Abdalla M and Russell I. Tariffs for the EuroQol health states based on modelling the individual VAS and TTO data of the York survey. In O'Hanlon and Buxton (1995).
20. Alli M, Ibrahim M, Lawrence D, Lockhart J, Laitner S, Brogan C. Survey on tackling health inequalities amongst older people in Brent and Harrow district of the UK: results from EQ-5D questionnaire. In Kind and Macran (2002a).
21. Angelsen V and Olsen J. QALY-league tables for a hospital. In O'Hanlon and Buxton (1995).
22. Arons A and Krabbe P. Considering cognition as a bolt-on dimension for the EQ-5D. Paper presented at the 28th Scientific Plenary Meeting of the EuroQol Group, Oxford, September 2011.
23. Attema A, Versteegh M, Oppe M, Brouwer W, Stolk E. Lead time TTO: leading to better health state valuations? In Yfantopoulos (2010).
24. Augestad L, Rand-Hendriksen K, Kristiansen I, Stavem K. Learning effects in EQ-5D TTO valuation. In Yfantopoulos (2010).
25. Augustovski F, Irazola V, Velazquez A, Gibbbons L, Craig B. To develop a set of EQ-5D health state values for the Argentine general population. In Scalone and Mantovani (2008).
26. Badia X. (Ed.) 25th Scientific Plenary Meeting of the EuroQol Group, September 2006, Barcelona. IMS Health Barcelona, 2007.
27. Badia X, Femandez E, Segura, A. Influence of socio-demographic and health status variables on evaluation of health states in a Spanish population. European Journal of Public Health 1995a; 5:87-93.
28. Badia X, Herdman M, Segura A. (Eds.). EuroQol Plenary Meeting Barcelona October 1995. Institut Universitari de Salut Pública de Catalunya, 1996.
29. Badia X, Herdman M, Roset M. (Eds.). 16th Plenary Meeting of the EuroQol Group Discussion Papers, Sitges, Spain, November 1999. Institut Universitari de Salut Pública de Catalunya, 2000.
30. Badia X, Roset M, Perulero N. Validation of the EQ-5D to be used in children with persistent asthma. In Pickard (2004).
31. Badia X, Roset M, Sara M, Herdman M. The Spanish VAS tariff based on valuations of EQ-5D health states from the general population. In Rabin et al (1998).
32. Badia X, Saez M, Pinto JL. Is the EuroQol data produced in an interval scale? Applying method of successive intervals with the Spanish EuroQol data. In O'Hanlon and Buxton (1995b).
33. Bailey H and Kind P. An evaluation of some approaches to the design of discrete choice experiments to elicit EQ-5D health state valuations. In Scalone and Mantovani (2008).
34. Bailey H and Kind P. Does time trade-off capture 'true' preferences for EQ-5D health states? In de Pouvourville (2009).
35. Bereza BG, Machado M, Einarson TR. Systematic review and quality assessment of economic evaluations and quality-of-life studies related to generalized anxiety disorder. Clinical Therapeutics 2009;31:1279-308.
36. Bergner M, Bobitt R, Kressel S, Pollard W, Gilson B, Morris J. The Sickness Impact Profile: conceptual formulation and methodology for the development of a health status measure. International Journal of Health Services 1976; 6:393-415.
37. Betegón L and Badia X. Discussion paper review of the use of the EQ-5D in cost-utility analysis. In Badia (2007).
38. Björk S. (Ed.) EuroQol Conference Proceedings, Lund, October 1991. Swedish Institute for Health Economics, 1992.
39. Björk S and Althin R. Health states considered worse than being dead. In Björk (1992).
40. Björk S and Norinder A. The weighting exercise for the Swedish version of the EuroQol. In O'Hanlon and Buxton (1995).
41. Bonsel G. One tariff for EuroQol - methodological issues relevant for the modelling of EuroQol data. In O'Hanlon and Buxton (1995).
42. Bonsel G. The utility of public health. Paper given at the Second Annual Meeting of Health Technology Assessment International, Rome, 2005.
43. Brazier J, Roberts J, Tsuchiya A. A comparison of the EQ-5D and SF-6D across seven patient groups. In Norinder et al (2002).
44. Brooks R with the EuroQol Group. EuroQol: the current state of play. Health Policy 1996; 37:53-72.
45. Brooks R, Rabin R, de Charro F. The Measurement and Valuation of Health Status using EQ-5D: A European Perspective. Kluwer. 2003.
46. Bryan S and Longworth L. EQ-5D versus SF-6D: why the disparity? In Kind and Macran (2002).
47. Bryan S, Jowett S, Hardyman W, Bentham P. Does the EQ-5D "anxiety/depression" item measure anxiety, depression, both or neither? In Pickard (2004).
48. Buckingham K, Devlin N, Hansen P. Does it matter whose valuations are used to estimate health state tariffs, and which tariffs are used for CUA? In Cabasés and Gaminde (2001)
49. Busschbach Jv. De Validiteit van QALYs. Gouda Quint, Arnhem, 1994.
50. Busschbach Jv, Bonsel G, de Charro F. (Eds.) EuroQol Plenary Meeting Rotterdam October 1993. Erasmus University, 1994.
51. Busschbach J, Rabin R, de Charro F. (Eds.) 24th Scientific Plenary Meeting of the EuroQol Group Proceedings, Kijkduin-The Hague, the Netherlands, September 2007. EuroQol Group Executive Office, 2007.
52. Busschbach Jv, Hessing D, de Charro, F. An empirical comparison of four measurements of quality of life: standard gamble, time trade-off, the Euroqol visual analog scale and the Rosser & Kind matrix. In Sintonen (1993).
53. Busschbach Jv, McDonnell J, van Hout B. Testing different parametric relations between the EuroQol health description and health valuations in students. In Nord (1997a).
54. Busschbach J, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Dolan P, Greiner W, Kind P, Krabbe P, Ohinmaa A, Roset M, Sintonen H, Tsuchiya A, Williams A, Yfantopoulos J, de Charro F. A comparison of EQ-5D time trade-off values obtained in Germany, the United Kingdom and Spain. In Brooks et al (2003).
55. Cabasés JM and Gaminde I. (Eds.) 17th Plenary Meeting of the EuroQol Group Discussion Papers, Pamplona, Spain, September 2000. Universidad Pública de Navarra, 2001.
56. Cabasés J and Sanchez E. Valuation of 5-level states and back-compatibility with existing 3-level valuation sets: a Bayesian approach. In Stavem (2005).
57. Cabasés J, Gaminde I, Ugalde J, Pozo F. Social elicitation of EQ-5D health states preferences through person Trade off (PTO). In Cabasés and Gaminde (2001).
58. Cadenas E, Perulero N, Lizán L, Badia X. The use of the EQ-5D in patients with osteoporosis. In Badia (2007).
59. Carr-Hill R. Health related quality of life measurement-Euro style. Health Policy 1992; 20:321-328.
60. Chevalier J, Devlin N, Parkin D, de Pouvourville G. Comparison of the VAS questionnaire and an experimental scoring method. In de Pouvourville (2009).
61. Chevalier J and de Pouvourville G. Testing of a new 5 level version of the EQ-5D in France. In Scalone and Mantovani (2008).
62. Chevalier J and de Pouvourville G. Valuing EQ-5D using Time Trade-Off in France. In de Pouvourville (2009).
63. Chuang L. Estimating domestic values for EQ-5D health states using imported national survey data. In Busschbach et al (2007).
64. Chuang L and Kind P. The effect of EQ-5D health state selection in the valuation. In Busschbach et al (2007).
65. Chuang L, Weatherly H, Kind P. The role of ranking in the EQ-5D valuation protocol. In de Pouvourville (2009).
66. Chuang L, Zarate V, Kind P. The distribution of values for health. In Scalone and Mantovani (2008).
67. Chuck A, Ohinmaa A, Adamowicz W, Jacobs P, Dick B, Rashiq S. Is there an association between Willingness to Pay and the EQ-5D Index Score? In Busschbach et al (2007).
68. Claes C, Greiner W, Uber A, Graf V.D. Schulenberg J-M. An interview-based comparison of the TTO and VAS values given to EuroQol states of health by the general German population. In Greiner et al (1999).
69. Claes C, Greiner W, Uber A, Graf V.D. Schulenberg J-M. The new German version of the EuroQol quality of life questionnaire. In Rabin et al (1998).
70. Clayson D, Wild D, Quarterman P, Duprat-Lomon I, Kubin M, Coons S. A comparative review of health-related quality-of-life measures for use in HIV/AIDS clinical trials. Pharmacoeconomics 2006; 24:751-65.
71. Cleemput I, Kind P, Kesteloot K. Re-scaling social preference data: implications for modelling. In Kind and Macran (2002a).
72. Cleemput I, Kesteloot K, Moons P, Vanrenterghem Y, Van Hooff J, Squifflet J, Clouth J, Schmidt P, Möser G, Greiner W. Estimating EQ-5D utilities applying structural equation modelling (SEM) for the German population. In Busschbach et al (2007).
73. Coons S and Johnson J. Comparison of the EQ-5D and SF-12 in an adult US-based population sample. In Nord (1997a).
74. Craig B. From a different angle: a novel approach to health valuation. In de Pouvourville (2009).
75. Craig B and Busschbach J. Replacing ad hoc adjustments for TTO values below death with a consistent theoretical model: increasing validity and power. In Scalone and Mantovani (2008).
76. Craig B and Pickard AS. Variability in QALY values for chronic conditions. In de Pouvourville (2009).
77. Craig B, Busschbach J, Salomon J. Ordinal valuation of health states: a seven country comparison. In Badia (2007a).
78. Craig B, Busschbach J, Salomon J. International valuation set for EQ-5D health states. In Busschbach et al (2007b).
79. de Charro F, Busschbach Jv, Essink-Bot M-L, van Hout B, Krabbe P. Some considerations about negative health states for EQ-5D health states. In Badia et al (1996).
80. de Haan R, Aaronson N, Limburg M, Hewer R, van Crevel H. Measuring quality of life in stroke. Stroke 1993; 24:320-7.
81. de Pouvourville G. (Ed.) 26th Scientific Plenary Meeting of the EuroQol Group Proceedings, Paris, France, September 2009. EuroQol Group Executive Office, 2009.
82. de Wit A, Merkus M, de Charro F. Measuring utilities in an end-stage renal disease population. In Badia et al (1996).
83. de Wit A, Busschbach Jv, de Charro F. Sensitivity and perspective in the valuation of health status: whose values count? In Greiner et al (1999).
84. Department of Health. The NHS Outcomes Framework 2011/12. NHS Department of Health (2010).
85. Derrett S, Black J, Herbison G. Outcome after injury: a systematic literature search of studies using the EQ-5D. Journal of Trauma 2009; 67:883-90.
86. Derrett S, Black J, Herbison G. EQ-5D and injury: a systematic review. In Scalone and Mantovani (2008).
87. Devlin N and Parkin D. Guidance to users of EQ-5D value sets. In Szende et al (2007).
88. Devlin N, Buckingham K, Shah K, Tsuchiya A, Tilling C, Wilkinson G, van Hout B. A comparison of alternative variants of the lead and lag time TTO. In Yfantopoulos (2010).
89. Devlin N, Hansen P, Kind P, Williams A. The health state preferences and logical consistencies of New Zealanders: a tale of two tariffs. In Cabasés and Gaminde (2001).
90. Devlin N, Hansen P, Selai C. Respondents' perception of an EQ-5D valuation questionnaire: insights from a self-completed VAS survey. In Norinder et al (2002a).
91. Devlin N, Hansen P, Macran S. A "new and improved" EQ-5D valuation questionnaire?: Results from a pilot study. In Kind and Macran (2002b).
92. Devlin N, Parkin D, Browne J. Using the EQ-5D as a performance measurement tool in the NHS. In Scalone and Mantovani (2008).
93. Dolan P. Search for a critical appraisal of EuroQol: a response by the EuroQol Group to Gafni and Birch. Health Policy 1994; 28:67-69.
94. Dolan P. Modelling valuations for EuroQol health states. In O'Hanlon and Buxton (1995).
95. Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: results from a UK general population survey. Discussion Paper 138, Centre for Health Economics, York, 1995.
96. Dolan P, Gudex C, Kind P, Williams A. Valuing health states: a comparison of methods. Journal of Health Economics 1996a; 15:209-231.
97. Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study. Health Economics 1996b; 5:141-154.
98. Dyer M, Goldsmith K, Sharples L, Buxton M. A review of health utilities using the EQ-5D in studies of cardiovascular disease. Health and Quality of Life Outcomes. 2010; 28; 8:13.
99. Elliott V, Rodgers D, Brett S. Systematic review of quality of life and other patient-centred outcomes after cardiac arrest survival. Resuscitation 2011; 82:247-56.
100. Essink-Bot M-L and Bonsel G. A common core for utility measurement: The Bergen op Zoom Survey. Institute for Medical Technology Assessment, Rotterdam, 1989.
101. Färe R, Grosskopf S, Roos P. Comparing states of health. In Stavem (2005).
102. Fox-Rushby J. First steps to assessing semantic equivalence of EQ-5D: Results of a questionnaire survey to members of the EuroQol Group. In Nord (1997)
103. Fox-Rushby J and Badia X. Reviewing international language versions of the EuroQol Instrument: challenges for the future. In Badia et al (1996).
104. Fox-Rushby J and Selai C. What concepts does the EQ-5D measure? Intentions and interpretations. In Brooks et al (2003).
105. Fukuda T, Hamashima C, Hisashige A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Tamura M, Tsuchiya A. Estimating a EuroQol value set: the case of Japan. In Badia et al (2000).
106. Gaebel K, Pullenayegum E, Krabbe P, Oppe M, Xie F. Use of Discrete Choice Experiment in measuring preferences: binary or triplet? Paper presented at the 28th Scientific Plenary Meeting of the EuroQol Group, Oxford, September 2011.
107. Gafni A and Birch S. Searching for a common currency: critical appraisal of the scientific basis underlying European harmonization of the measurement of health related quality of life (EuroQol). Health Policy 1993; 23(3):219-228.
108. Gaminde I and Cabasés J. Measuring valuations for health states amongst the general population in Navarra (Spain). In Badia et al (1996).
109. Gharagebakyan G, Ghukasyan H, Williams A, Szende A. Social inequalities in self-reported health: is Armenia different from Slovenia? In Prevolnik Rupel (2003).
110. Golicki D, Jakubczyk M, Niewada M, Wrona W, Busschbach J. Valuing EQ-5D with time tradeoff for the Polish population. In Scalone and Mantovani (2008).
111. Golicki D, Zawodnik S, Janssen M, Kiljan A, Hermanowski T. Psychometric comparison of EQ-5D and EQ-5D-5L in student population. In Yfantopoulos (2010).
112. Grafvd Schulenberg J-M, Claes C, Greiner W, Uber A. The German version of the EuroQol Quality of Life Questionnaire. In Badia et al (1996).
113. Greiner W, Graf V.D. Schulenberg J-M, Piercy J. (Eds.) EuroQol Plenary Meeting Hannover October 1998 Discussion Papers. Uni-Verlag Witte, 1999.
114. Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, de Charro F. A European EQ-5D valuation set. In Brooks et al (2003).
115. Gu NY, Craig B, Doctor J. Evaluating EQ-5D items using the Rasch Models in a U.S. representative sample. In Scalone and Mantovani (2008).
116. Gudex C. Are we lacking a dimension of energy in the EuroQol Instrument? In Björk (1992).
117. Gudex C. The descriptive system of the EuroQol Instrument. In Badia et al (1996).
118. Gudex C and MacDonagh R. Change in reported health status following urological surgery: preliminary results. In Busschbach et al (1994).
119. Gudex C, Kind P, Dolan P. The valuation of death. In Sintonen (1993).
120. Gusi N, Ortega Y, García-Martin Y, Monge M. Physical activity, lifestyle and health-related quality of life of secondary students in Extremadura, Spain. In Norinder et al (2002).
121. Haagsma J, Janssen B, Bonsel G. Comparing generic and disease specific health state valuations by a laymen panel. In Stavem (2005).
122. Hare J, Leese B, Hardman G. Applications of EuroQol (EQ5D) in general practice: an exploratory study. In Rabin et al (1998).
123. Hennessy S and Kind P. Measuring health status in children: developing and testing a childfriendly version of EQ-5D. In Kind and Macran (2002a).
124. Herdman M, Fox-Rushby J, Rabin R, Badia X, Selai C. Producing other language versions of the EQ-5D. In Brooks et al (2003).
125. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research 2011; 20:1727-1736.
126. Herdman M, Kind P. Chevalier J, Gudex C, de Pourvourville G. Investigation of labels for additional EQ-5D levels: Results of main study + 1. In Busschbach et al (2007).
127. Herdman M, Sanz L, Lloyd A, Badia X, Gudex, C. Qualitative testing of two new 5-level versions of the EQ-5D in Spain: Preliminary study results. In Scalone and Mantovani (2008).
128. Hunt S and McEwen J. The development of a subjective health indicator. Social Health and Illness 1980; 2:231-246.
129. Ikeda S, Sakai I, Tamura M, Tsuchiya A. VAS valuations of hypothetical health states in Japan. In Cabasés and Gaminde (2001).
130. Ikegami N, and Ikeda S. Health status in the Japanese population: results from the Japanese EuroQol study. In Badia et al (2000).
131. Janssen M. The discriminatory power of the EQ-5D, HU12, HU13 and the SF-6D in 13 patient groups. In Busschbach et al (2007).
132. Janssen M and Bonsel G. Towards a HUI-fication of the EQ descriptive system: should the EQ descriptive system be extended from three to five levels? A universal modelling strategy with an empirical pilot. In Pickard (2004).
133. Janssen M, Haagsma J, Bonsel G. Comparing the standard EQ-5D three level system with a five level version. In Stavem (2005).
134. Janssen M, Birnie E, Bonsel G. Quantification of the level descriptors for the standard EQ-5D three level system and a five level version according to 2 methods. Quality of Life Research 2008a;17:463-473.
135. Janssen M, Birnie E, Bonsel G. Quantification of the level descriptors for the standard EQ-5D three level system and a five level version according to 2 methods. In Badia (2007).
136. Janssen M, Birnie E, Haagsma J, Bonsel G. Comparing the standard EQ-5D three level system with a five level version. Value in Health. 2008b;11:275-284.
137. Janssen M, Busschbach J, Golicki D, Niewada M, Scalone L, Swinburn P, Pickard AS. Measurement properties of the EQ-5D-5L compared to EQ-5D-3L in 8 patient groups. Paper presented at the 28th Scientific Plenary Meeting of the EuroQol Group, Oxford, September 2011b.
138. Janssen M, Gorts R, Hazenberg C, Krabbe P. Discrepancies between the EQ-5D societal index and patient derived valuations. In Prevolnik Rupel (2003).
139. Janssen M, Lubetkin E, Pickard AS. The use of the EQ-5D preference-based health status measure in adults with type 2 diabetes mellitus. In de Pouvourville (2009).
140. Janssen M and Bonsel G. Estimating preference weights for chronic multimorbidity: Don't add, multiply. In Scalone and Mantovani (2008).
141. Janssen M, Lubetkin E, Sekhobo J, Pickard AS. The use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus. Diabetic Medicine 2011a; 28:395-413.
142. Jelsma J and Matyida N. The development of an adapted version of the EQ-5D for infants under the age of 36 months. In Prevolnik Rupel (2003).
143. Jelsma J and Ferguson G. The determinants of HRQoL in able-bodied and disabled children. In de Pouvourville (2009).
144. Johnson J, Ohinmaa A, Murti B, Sintonen H, Coon S. Comparison of Finnish and US-based visual analog scale valuations of the EQ-5D measure. Medical Decision Making 2000; 20:281-289.
145. Johnson J, Ergo A, Coons S. Valuation of the EuroQol (EQ-5D) in an adult US sample. In Nord (1997a).
146. Johnson J, Luo N, Shaw J, Kind P, Coons S. Valuations of EQ-5D health states: are the US and UK different? In Pickard (2004).
147. Kaplan R, Bush J, Berry C. Health status: types of validity and the index of wellbeing. Health Services Research 1976; 11:478-507.
148. Karnofsky D and Burchenal J. The clinical evaluation of chemotherapeutic agents in cancer. In Macleod C. Evaluation of Chemotherapeutic Agents. Columbia UP, 1949.
149. Kerim-Sade C, and Wasem J. An external control of the validity of the German EQ-5D questionnaire. In Badia et al (2000).
150. Kind P. Foreword. In Kind P et al (2005a).
151. Kind P. Forging the link between VAS and TTO: Is this the end for utility measurement? In Norinder et al (2002).
152. Kind P. In Memoriam: Alan Williams (1928-2005). Value in Health 2005c; 8: 615-617.
153. Kind P. Valuing EQ-5D health states - a VAStly simpler solution? In Busschbach et al (2007).
154. Kind P. Valuing health benefits using EQ-5D: the W Lothian question. In Stavem (2005b).
155. Kind P and Gudex C. Measuring health status in the community: a comparison of methods. Journal of Epidemiology and Community Health 1991; 48:86-91.
156. Kind P and Macran S. (Eds.) 19th Plenary Meeting of the EuroQol Group Discussion Papers, York, UK, September 2002. Centre for Health Economics, University of York, 2002a.
157. Kind P and Macran S. Levelling the playing field: increasing the number of response categories in EQ-5D. In Kind and Macran, 2002b.
158. Kind P, Brooks R, Rabin R (Eds.) EQ-5D Concepts and Methods. Kluwer, 2005.
159. Kind P, Hennessy S, Macran S. The value of hypothetical and "real" EQ-5D health states and other things: a fairytale for the childrens' session at the EuroQol Scientific Plenary. In Pickard (2004).
160. Kind P, Leese B, Hardman G. Demonstrating the value of EQ-5D as a tool for monitoring health status in primary care. In Rabin et al (1998).
161. Kind P, Macran S, Hennessy S. Measuring social preferences for EQ-5D health states: results from a saturation study. In Prevolnik Rupel (2003).
162. Klose, K and Greiner W.: Developing a cognitive dimension as a bolt-on for the EQ-5D-Y in Germany. Poster presented at the 28th Scientific Plenary Meeting, Oxford, UK, September 2011.
163. Kohlmann T, Gnanasakthy A, Naujoks C. Are category scores for EQ-5D derived from psychometric models equivalent to the results of preference-based valuations? In Norinder et al (2002).
164. Kok E, Stolk E, Busschbach Jv. Influences of the number of health states on time trade-off. In Cabasés and Gaminde (2001).
165. Krabbe P. Good day sunshine: about biases, irregularities and inconsistencies in valuation of health states. In Kind and Macran (2002a).
166. Krabbe P. Revealing preference patterns of health states with singular value decomposition. In Prevolnik Rupel (2003).
167. Krabbe P. Thurstone scaling as a measurement method to derive health-state quantifications. In Stavem (2005).
168. Krabbe P, Bonsel G, Essink-Bot M-L. Modelling: multiple classification analyse and logit transformation. In O'Hanlon and Buxton (1995).
169. Krabbe P, de Charro F, Essink-Bot M-L. Issues in the harmonisation of valuation and modelling. In Badia et al (1996).
170. Krabbe P, Stalmeier P, Lamers L, Busschbach Jv. An experimental study on three principal biases of the visual analogue scale. In Pickard (2004).
171. Krabbe P, Stouthard M, Esssink-Bot M-L, Bonsel G. The effect of adding a cognitive dimension to the EuroQol multi-attribute health status classification system. In Rabin et al (1998).
172. Krabbe P, Stouthard M, Esssink-Bot M-L, Bonsel G. The effect of adding a cognitive dimension to the EuroQol multi-attribute health status classification system. Journal of Clinical Epidemiology 1999; 52:293-301.
173. Krabbe P. Presentation of design, methods and 'common core' results of the multi-country study, parts 1 and 2. Papers presented at the 28th Scientific Plenary meeting of the EuroQol Group, Oxford, September 2011.
174. Lai T. Computer assisted interview collection and fully electronic management of EQ data in Estonia. In Pickard (2004).
175. Lamers L. Adjustment of EQ-5D TTO valuation sets for use of an EQ-5D five level descriptive system: a pragmatic approach. In Stavem (2005).
176. Lamers L, McDonnell J, Stalmeier P, Krabbe P, Busschbach J. A Dutch value set for the EQ-5D: first results. In Prevolnik Rupel (2003).
177. Leese B, Kind P, Hardman G. Measuring outcomes - managing performance: roles for EQ-5D in delivering primary health care services? In Kind and Macran (2002a).
178. Lloyd A and Quadri N. Testing alternative labels for a UK English five level version of EQ-5D. In Scalone and Mantovani (2008).
179. Lloyd A, Nafees B, Rousculp M, Secnik-Boye K. Rich versus simple descriptive systems: does it make any difference? In Busschbach et al (2007).
180. Lloyd A, Swinburn P, Edson E, Bowman L, Boye K, Janssen M, Pickard AS, de Charro F. Development of the EQ-5D-Psoriasis. In Yfantopoulos (2010).
181. Luo N, Johnson J, Shaw J, Coon S. Relative efficiency of the EQ-5D, HU12, and HU13 in a US population survey. In Pickard (2004).
182. Luo N, Li M, Liu G. Investigation of labels for a 5-level EQ-5D descriptive system in Chinese. In de Pouvourville (2009).
183. Luo N, Li M, Liu G, Lloyd A, de Charro F, Herdman M. Developing the Chinese version of the new 5-level EQ-5D descriptive system: the response scaling approach. Quality of Life Research (2012).
184. Macran S. Recalled versus initial health status: EQ-5D in retrospect. In Kind and Macran (2002a).
185. Macran S. The relationship between religious belief and values for the state dead. In Prevolnik Rupel (2003).
186. Macran S and Kind P. An Illness Atlas for EQ-5D. In Stavem (2005).
187. Macran S and Kind P. EQ-5D valuations from a British national postal survey. In Cabasés and Gaminde (2001)
188. Macran S and Kind P. Valuing EQ-5D health states using a modified MVH protocol: preliminary results. In Badia et al (2000).
189. Manninen M, Ohinmaa A, Winblad I, Remes A, Viramo P, Liuska E, Hynninen, M. Health-related quality of life of care-givers of dementia patients. In Prevolnik Rupel (2003).
190. Mayo N, Goldber M, Kind P. Performance of the EuroQol EQ-5D in a Canadian population. In Rabin et al (1998.)
191. McLernon D, Dillon J, Donnan P. Health-state utilities in liver disease: a systematic review. Medical Decision Making 2008; 28:582-92.
192. Meyer-Moock S, Moock J, Hessel F, Kohlmann T. Awareness, relevance and potential use of the EQ-5D in German health care decision making processes. In Yfantopoulos (2010).
193. Mills T, Law S, Walt J, Buchholz P, Hansen J. Quality of life in glaucoma and three other chronic diseases: a systematic literature review. Drugs and Aging 2009; 26:933-50.
194. Moock J and Kohlmann T. Comparing the EQ-5D, SF-6D, HU12, QWB-SA and 15D: Which measure can be recommended for use in the German system of medical rehabilitation? In Pickard (2004).
195. Mulhern B, Tsuchiya A, Rowen D, Devlin N, Bansback N, Longworth L, Brazier J. Health state valuation and mode of administration: head to head comparison of on-line and CAPI. Paper presented at the 28th Scientific Plenary meeting of the EuroQol Group, Oxford, September 2011.
196. Murti B, Johnson J, Ohinmaa A, Sintonen H, Coons S. Comparison of Finnish- and US-based VAS valuations of the EQ-5D. In Rabin et al (1998).
197. Murti B, Johnson J, Ohinmaa A, Coons S. Comparison of Finnish and US-based VAS valuations of the EQ-5D. In Greiner et al (1999).
198. Nord E. The EuroQol Group: Papers written as part of the EuroQol enterprise, March 1992. In Sintonen (1993a).
199. Nord E. The EuroQol Group: Systematic list of points made and lessons learned in the EuroQol enterprise, March 1992. In Sintonen (1993b).
200. Nord E. The use of EuroQol values in QALY calculations. In Björk (1992).
201. Nord E. The validity of a visual analogue scale in determining social weights for health scales. International Journal of Health Planning and Management 1991; 6:234-242.
202. Nord E. (Ed.) EuroQol Plenary Meeting Oslo October 1996 Conference Porceedings. National Institute of Public Health, Oslo, 1997a.
203. Nord E. Time trade-off scores in patients with chronic disease. Comparison with the York hypothetical TTO tariff. In Nord (1997b).
204. Nord E, Badia X, Rué M, Sintonen H. Hypothetical evaluations of health states versus patients' self-ratings. In Badia et al (1996).
205. Nord E, Richardson J, Macarounas-Kirchmann K. Social evaluation of health care versus personal evaluation of health states: evidence on the validity of four health-state scaling instruments using Norwegian and Australian surveys. International Journal of Technology Assessment in Health Care 1993; 9:463-478.
206. Norinder A and Krabbe P. On the relationship between trade-off and scaling techniques for the valuation of health states. In Norinder et al (2002).
207. Norinder A, Pedersen KM, Roos P. (Eds.) Proceedings of the 18th Plenary Meeting of the EuroQol Group, Copenhagen, Denmark, September 2001. Swedish Institute for Health Economics, 2002.
208. Noyes J, Edwards RT. EQ-5D for the assessment of health-related quality of life and resource allocation in children: a systematic methodological review. Value in Health 2011;14:1117-29.
209. Nuria L, Badia X, Montse R, Nuria P, Noelia B, Neus C. Use of the Spanish version of the EQ-5D in different disease areas and population sub-groups. In Stavem (2005).
210. O'Hanlon M and Buxton M. (Eds.) EuroQol Plenary meeting London October 1994 Conference Proceedings. Health Economics Research Group, Brunel University, 1995.
211. Ohinmaa A. Modelling valuations for EuroQol health states. Comparison of three tariff systems based on the data collected in the University of York. In O'Hanlon and Buxton (1995).
212. Ohinmaa A and Sintonen H. Inconsistencies and modelling of the Finnish EuroQol (EQ-5D) preference values. In Greiner et al (1999).
213. Ohinmaa A and Sintonen H. The EQ-5D outcomes produced by different tariffs. In Nord (1997a).
214. Ohinmaa A, Eija H, Sintonen H. Modelling EuroQol values of the Finnish adult population. In Badia (1996).
215. Oppe M and de Charro F. Estimating TTO-based value sets for EQ-5D using medians. In de Pouvourville (2009).
216. Oppe M and van Hout B. The optimal hybrid: Experimental design and modelling of a combination of TTO and DCE. In Yfantopoulos (2010).
217. Oppe M, Oppe, de Charro F. Uncertainty in model applications from TTO studies. In Busschbach et al (2007a).
218. Oppe M, Szende A, de Charro F. Development of a methodology to gain insight on the use of EQ-5D in different disease areas. In Stavem (2005).
219. Oppe M, van Hout B, de Charro F. A simulation study to explore the possibilities of using DCE as a technique to elicit EQ-5D value sets. In Busschbach et al (2007b).
220. Papaioannou D, Brazier J, Parry G How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review. Value in Health 2011;14:907-20.
221. Parkin D and Devlin N. In defence of the visual analogue scale? In Prevolnik Rupel (2003).
222. Parkin D and Devlin N. Is there a case for using visual analogue scale valuations in cost-utility analysis? Health Economics 2006; 15:653-664.
223. Parkin D, Devlin N, Sharma P. A deathless and VAS-free EQ-5D self-completion valuation questionnaire. In Stavem (2005).
224. Parkin D, Rice A, Jacoby A. Use of the EQ VAS in a daily patient diary. In Badia et al (2000).
225. Patrick D, Bush J, Chen M. Methods for measuring levels of well-being for a health status index. Health Services Research 1973; 8:228-245.
226. Persson U, Glenngard A, Hjortsberg C. Estimating the willingness to pay for a QALY in Sweden: a pilot study. In Scalone and Mantovani (2008).
227. Pickard AS. (Ed.) 21st Scientific Plenary Meeting of the EuroQol Group Discussion Papers, September 2004, Chicago, USA. Center for Pharmacoeconomics Research, University of Illinois, Chicago, 2004.
228. Pickard AS and Lin F. Is EQ-5D inferior in content to disease-specific utility measures? In Yfantopoulos (2010).
229. Pickard AS, De Leon M, Kohlmann T, Cella D, Rosenbloom S. Psychometric comparison of the standard EQ-5D to a 5-level version in cancer patients. In Badia (2007a).
230. Pickard AS, Kohlmann T, Cella D, Rosenbloom S, Bonsel G, Janssen M. A crosswalk for a 5 level version of EQ-5D. Come together: use of IRT models to derive preference-based algorithms for a 5 level version. In Badia (2007b).
231. Pickard AS, Wilke C, Hsiang-Wen L, Lloyd A. Impact of cancer on health related quality of life: evidence using the EQ-5D. In Badia (2007c).
232. Pickard AS, Wilke C, Jung E, Patel S, Stavem K, Lee T. Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Respiratory Medicine 2008;102:519-36.
233. Pickard AS, Wilke C, Jung E. Patel S, Stavem K, Lee T. Use of a preference-based measure of health (EQ-5D) in COPD and asthma. In Busschbach (2007d).
234. Pickard AS, Wilke C, Lin H, Lloyd A. Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics 2007e; 25:365-84.
235. Pinto J.L. Checking the interval properties of different scaling methods: application to some EuroQol health states. In Badia et al (1996).
236. PJB Publications. SCRIP's 2000 pharmaceutical companies league tables. PJB Publications 2000.
237. Prevolnik Rupel V. (Ed.) 20th Plenary Meeting of the EuroQol Group Discussion Papers, Bled, Slovenija, September, 2003. Republic of Slovenia Ministry of Health, 2003.
238. Prevolnik Rupel V and Rebolj M. The Slovenian VAS tariff based on valuations of EQ-5D health states from the general population. In Cabasés and Gaminde (2001).
239. Rabin R, Busschbach Jv, de Charro F, Essink-Bot M-L, Bonsel G. (Eds.) EuroQol Plenary Meeting, Rotterdam, October 1997 Discussion Papers. Institute for Medical Technology Assessment, 1998.
240. Rabin R, Herdman M, Fox-Rushby J, Badia X. Exploring the results of translating the EQ-5D into 11 European languages. In Brooks et el (2003).
241. Ramos-Goñi J, Errea M, Stolk E, Herdman M, Rivero-Arias D, Cabasés J. Discrete choice (DC) models: anchor in death or in time trade-off (TTO) values? Spanish pilot study of the EQ-5D valuation project. Paper presented at the 28th Scientific Plenary meeting of the EuroQol Group, Oxford, September 2011.
242. Rand-Hendriksen K, Augestad L, Kristiansen I, Stavem K. Comparison of hypothetical and experienced EQ-5D valuation: relative weights of the 5 dimensions. In Yfantopoulos (2010).
243. Ravens-Sieberer U, Wille N, Badia X, Bonsel G, Burström K, Cavrini G, Devlin N, Egmar A-C, Gusi N, Herdman M, Jelsma J, Kind P, Olivares P, Scalone L, Greiner W. Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. Quality of Life Research 2010; 19:887-97.
244. Rebolj M and Prevolnik Rupel V. Socioeconomic inequalities in health of the Slovenian population measured by the EQ-5D instrument. In Norinder et al (2002).
245. Rebolj M, Oppe S, Oppe M, Rabin R, Szende A, Cleemput I, de Charro F, Williams A. What light does EQ-5D shed on international differences in self-reported health problems by age, sex and educational level? In Kind and Macran (2002a).
246. Roset M, Badia X, Herdman M, Kind P. A comparison of English and Spanish general population TTO values for EQ-5D health states: preliminary results. In Greiner et al (1999).
247. Roset M, Badia X, Benavides A, Herdman M. The validity of the EQ-5D in children with asthma. In Badia et al (2000).
248. Rosser R and Kind P. A scale of valuations of states of illness: is there a social consensus? International Journal of Epidemiology 1978; 7:347-358.
249. Scalone L, Ciampichini R, Fagiuoli S, Gardini I, Gaeta L, Del Prete A, Magini G, Baldan A, Mantovani L. Comparing the standard EQ-5D-3L versus 5L version for the assessment of health of patients with liver diseases. In Yfantopoulos (2010).
250. Scalone L, Cristiani M, Cortesi P, Morsanutto A, Meneghini M, Mantovani L. Assessment of preferences toward different health states traded off with life duration and death: further application and investigation of the performance of Discrete Choice Analysis. In de Pouvourville (2009).
251. Scalone L and Mantovani L. (Eds.) 25th Scientific Plenary Meeting of the EuroQol Group Proceedings, Baveno, Italy, September 2008. EuroQol Group Executive Office, 2008.
252. Secnik K, Matza L, Mannix S, Sallee F. Use of the EQ-5D proxy version in a sample of parents who have children diagnosed with attention deficit/hyperactivity disorder (ADHD). In Prevolnik Rupel (2003).
253. Secnik, K, Matza, L, Mannix, S. The proxy EQ-5D as a quality of life measure in UK children with attention deficit/hyperactivity disorder. In Pickard (2004).
254. Selai C. The use of the EuroQol descriptive (pages 2 and 3) with patients at the Institute of Neurology, London. In O'Hanlon and Buxton (1995).
255. Selai C. Four levels and a funeral: preliminary testing of a four-level EuroQol descriptive classification system. In Badia et al (1996).
256. Selai C. The problem of inconsistencies in elicited EQ values: discussion paper. In Badia et al (2000).
257. Selai C. Testing the EuroQol 3-level and 4-level descriptive classification systems. In Nord (1997a).
258. Selai C, Gaminde I, Herdman M, Johnson J, Rabin R. EQ-5D: modes of administration. In Brooks et al (2003).
259. Selai C and Rosser R. Eliciting EuroQol descriptive data and utility scale values from seriously ill in-patients: the pharmaco-economic relevance. In Busschbach et al (1994).
260. Shah K, Lloyd A, Devlin N. Understanding participants' responses to valuation tasks: implications for EQ-5D-5L valuation studies. Paper presented at the 28th Scientific Plenary Meeting of the EuroQol Group, Oxford, September 2011.
261. Shaw J, Johnson J, Iannacchione V, Coons S. US valuation of the EQ-5D health states: methods, sampling, and preliminary analyses. In Prevolnik Rupel (2003).
262. Shaw J, Luo X, Pickard AS, Walton S. Efficiency of estimation with the the US population median-based EQ-5D Index: findings from the Medical Expenditure Panel Survey. In Yfantopoulos (2010a).
263. Shaw J, Zhan L, Oppe M. Evaluation of conditional median models of EQ-5D health states preferences using data collected in four countries. In Yfantopoulos (2010b).
264. Sintonen H. An approach to measuring and valuing health states. Social Science and Medicine 1981; 15c: 55-65.
265. Sintonen H. (Ed.) EuroQol Conference Proceedings Helsinki October 1992. Department of Social Sciences, University of Kuopio, 1993.
266. Sintonen H, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, Greiner W, Krabbe P, Ohinmaa A, Roset M, de Charro F. Comparison of EQ-5D VAS valuations: analysis of background variables. In Brooks et al (2003).
267. Sintonen H. EuroQol vs. 15D: a comparison of two health-related quality of life measures. In O'Hanlon and Buxton (1995).
268. Solem C, Gu N, Pickard AS. Predicting VAS scores by EQ-5D Items and presence of disease: a bolt-on feasibility study. Paper presented at the 28th Scientific Plenary meeting of the EuroQol Group, Oxford, September 2011.
269. Stavem K. (Ed.) 22nd Plenary Meeting of the EuroQol Group Discussion Papers, Oslo, Norway, September 2005. Helse-Øst Health Services Research Centre, Lørenskog, 2005.
270. Steinbrocker O, Traeger C, Battman R. Therapeutic criteria in rheumatoid arthritis. Journal of the American Medical Association 1949: 140:653-662.
271. Stolk E, Krabbe P, Busschbach J. Using the Internet to collect EQ-5D norm scores: a valid alternative? In Busschbach et al (2007).
272. Stolk E, Oppe M, Scalone L, Krabbe P. Discrete choice modelling for the quantification of health states: the case of the EQ-5D. In Scalone and Mantovani (2008).
273. Stolk E and van Busschbach Jv. The performance of EuroQol in children. In Greiner et al (1999).
274. Stouthard M and Essink-Bot M-L. EuroQol 1991-The Rotterdam Survey-Results. In Björk (1992).
275. Szanto Z and Susansky E. Quality of life and social inequalities in the middle aged Hungarian population: a population survey utilization of the EQ-5D. In Prevolnik Rupel (2003).
276. Szende A and Williams A (Eds.) Measuring Self-Reported Population Health: An International Perspective based on EQ-5D. SpringMed Publishing 2004.
277. Szende A. The (potential) role of the EQ-5D in the international comparison of socioeconomic inequalities in health status. In Kind and Macran (2002a).
278. Szende A, Oppe M, Devlin N. (Eds.) EQ-5D Value Sets: Inventory, Comparative Review and User Guide. Springer 2007.
279. The EuroQol Group. EuroQol-A new facility for the measurement of health-related quality of life. Health Policy 1990; 16:199-208.
280. The EuroQol Group. Not a quick fix. Health Service Journal 1991;101(5279):29.
281. Thompson S, Holtzer-Goor K, Schaafsma R, Uyl-de Groot C. Use of a 5-level EQ-5D instrument without additional labels in patients with chronic lymphocytic leukaemia. In Badia (2007).
282. Tilling C, Devlin N, Tsuchiya A, Buckingham K. Time Trade Off valuation of EQ-5D states worse than dead: a feasibility study. In Scalone and Mantovani (2008).
283. Tosh J, Brazier J, Evans P, Longworth L. A review of generic preference-based measures of health-related quality of life in visual disorders. Value in Health 2012; 15:118-27.
284. Tsuchiya A, Brazier J, McColl E, Parkin D. A condition-specific instrument, a generic instrument, and a preference-based generic instrument. In Norinder et al (2002a).
285. Tsuchiya A, Brazier J, Roberts J. Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets in the UK. In Kind and Macran (2002b).
286. Tsuchiya A, Mulhern B, Buckingham K, Devlin N. Testing lead time TTO issues in an online environment. Paper presented at the 28th Scientific Plenary Meeting of the EuroQol Group, Oxford, September 2011.
287. van Agt H and Bonsel G. The number of levels in the descriptive system. In Busschbach et al (1994).
288. van Dalen H, Williams A, Gudex C. Lay people's evaluation of health: are there variations between different subgroups? Journal of Epidemiology and Community Health 1994; 48:248-253.
289. van Hout B and McDonnell J. Estimating a parametric relation between health description and health valuation using the EuroQol. In Björk (1992).
290. Vásquez-Polo F, Negrin M, Badia X, Roset M. A Bayesian model of cost-effectiveness with EQ-5D data. In Kind and Macran (2002a).
291. Weijnen T, Nieuwenhuizen M, Ohinmaa A, de Charro F. Construction of the EQ-net VAS and TTO databases. In Brooks et al (2003).
292. Wilke C, Karabastos G, Pickard AS. Application of Kernel regression item response theory for evaluation of EQ-5D 3L and 5L systems. In Scalone and Mantovani (2008).
293. Wilke C, Karabatsos G, Pickard AS. Comparison of patient and proxy health related quality of life ratings using parametric and nonparametric item response theory approaches. In de Pouvourville (2009).
294. Wille N, Badia X, Bonsel G, Burström K, Cavrini G, Devlin N, Egmar A-C, Greiner W, Gusi N, Herdman M, Jelsma J, Kind P, Scalone L, Ravens-Sieberer U. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Quality of Life Research 2010; 19:887-97.
295. Wille N, Hale S, Ravens-Sieberer U, Kohlmann T, Greiner W. Feasibility and preliminary validity of a German EQ-5D childrens version. In Stavem (2005).
296. Wille N, Ravens-Sieberer U. and the child-friendly task force on behalf of the EuroQol Group. Establishing definitions of the concepts included in CF-EQ-5D: A revision of the "Definition of EQ-5D concepts" for adults. In Badia (2007).
297. Williams A. Foreword. In Brooks et al (2003).
298. Wittrup-Jensen K, Lauridsen J, Gudex C, Brooks R, Pedersen KM. Estimating Danish EQ-5D tariffs using the time trade-off (TTO) and visual analogue scale (VAS) methods. In Norinder et al (2002).
299. Wittrup-Jensen K, Lauridsen J, Pedersen KM. Valuation of EQ-5D health states using the person trade-off method. In Badia (2007).
300. Yang Y, Brazier J, Tsuchiya A. The effect of adding a 'sleep' dimension to EQ-5D. Paper given at the Health Economists' Study Group Meeting, January 2008.
301. Yang Y, Rowen D, Brazier J, Tsuchiya A, Young T, Longworth L. Testing the impact of three add-ons to the EQ-5D: a pilot study. Paper presented at the 28th Scientific Plenary Meeting of the EuroQol Group, Oxford, September 2011.
302. Yfantopoulos J. Quality of life measurement and health production in Greece. In Greiner et al (1999).
303. Yfantopoulos J and Sintonen H. Comparison of the properties of the EQ-5D with the15D in Finland and Greece. In Norinder et al (2002).
304. Yfantopoulos J, Papagianopoulou V, Rachiotis G, Bechrakis P. Socio-economic inequalities in health status and HRQOL among manual and non-manual workers in Greece. In Prevolnik Rupel (2003).
305. Yfantopoulos J. (Ed.) 27th Scientific Plenary Meeting of the EuroQol Group Proceedings, Athens, Greece, September, 2010. EuroQol Group Executive Office, 2010.
306. Yu S, Shaw J, Chen S, Iannacchione V, Johnson J, Coons S. A median model of US EQ-5D health state preferences. In Busschbach et al (2007).